A G Olsson
- LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL studyAnders G Olsson
Department of Internal Medicine, University Hospital, Linkoping, Sweden
Eur J Cardiovasc Prev Rehabil 18:262-9. 2011..5 or 2.0 mmol/l in the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study. We explored how lipoprotein components related to cardiovascular disease (CVD) outcomes in these groups...
- HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacinA G Olsson
Department of Medicine and Health, Faculty of Health Sciences, Linkoping University, Linkoping, Bergviksvägen 48, SE 176 63 Bromma, Sweden
Nutr Metab Cardiovasc Dis 20:553-7. 2010..Long-term interventional studies with hard endpoints of both therapies are ongoing. Also both drugs, when proven efficient and safe, are eagerly needed in the prevention of cardiovascular disease...
- Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular diseaseAnders G Olsson
Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
Expert Opin Pharmacother 11:1715-26. 2010..In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density lipoprotein (LDL)-cholesterol and lipoprotein(a) and has been named the broad-spectrum lipid drug...
- Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemiaA G Olsson
Department of Medicine and Care, University Hospital, Linkoping, Sweden
Am J Cardiol 88:504-8. 2001..Over 6 weeks, rosuvastatin produced large, rapid, dose-dependent LDL cholesterol reductions and was well tolerated in hypercholesterolemic patients...
- A new statin: a new standardA G Olsson
Clinical Research Center, University Hospital, Linkoping, Sweden
Clin Cardiol 24:III18-23. 2001..Overall, these findings suggest that rosuvastatin is a promising new medication for the treatment of dyslipidemias...
- Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin RosuvastatinA G Olsson
Department of Medicine and Care, University Hospital, , Sweden
Am J Cardiol 87:33B-36B. 2001..5% reduction in LDL-C with each doubling of the rosuvastatin dose. Rosuvastatin treatment was well tolerated. Phase 3 clinical trials of this agent are under way...
- Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trialA G Olsson
Hälsouniversitet Institutionen för Internmedicin, Linkoping, Sweden
Clin Ther 23:45-61. 2001..A new extended-release (ER) formulation of fluvastatin 80 mg has been developed for once-daily treatment of primary hypercholesterolemia...
- Are early clinical effects of cholesterol lowering mediated through effects on inflammation?A G Olsson
Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden
Acta Physiol Scand 176:147-50. 2002..Statin treatment seems to be able to decrease this inflammatory response...
- Impaired cortisol response to acute stressors in patients with coronary disease. Implications for inflammatory activityJ Nijm
Department of Medicine, Högland Hospital, Eksjo, and Department of Medicine and Care, Division of Cardiology, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
J Intern Med 262:375-84. 2007..We hypothesized that an altered hypothalamic-pituitary adrenal (HPA) axis activity was linked to a disinhibited inflammatory activity in patients with coronary artery disease (CAD)...
- Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemiaH M Blomqvist
Division of Internal Medicine, Department of Medicine and Care, Clinical Research Center, Faculty of Health Sciences, Linkoping, Sweden
Scand J Clin Lab Invest 63:513-9. 2003....
- Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatmentS Lind
Department of Medicine and Care, Faculty of Health Sciences, Linkoping University, Stockholm, Sweden
J Intern Med 256:406-12. 2004..However, a phenotype very similar to FH may also be caused by defects in other genes like the genes for apolipoprotein (apo) B-100 or autosomal recessive hypercholesterolaemia (ARH)...
- The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitusT Lindstrom
Faculty of Health Sciences, Linkoping University, Sweden
Diabet Med 16:820-6. 1999..To study whether changes in endogenous insulin secretion at the same glycaemic control affect the plasma concentrations of lipoproteins in patients with Type 2 diabetes mellitus...
- The lower the better? Experiences from cardiovascular disease and stroke preventionA G Olsson
Internal Medicine, IMV, Berzelius Science Park, University Hospital, Linkoping, Sweden
Acta Neurol Scand Suppl 185:58-62. 2006
- Ultrasound determined carotid and femoral atherosclerosis in Lithuanian and Swedish men: the LiVicordia studyM Kristenson
Department of Health and Environment, Faculty of Health Sciences, Linkoping, Sweden
Atherosclerosis 151:501-8. 2000..32). These findings show that the higher coronary mortality noted in Lithuanian men goes together with a higher prevalence of early peripheral atherosclerosis...
- Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristicsN E Nielsen
Department of Cardiology, University Hospital, S 581 85 Linkoping, Sweden
J Intern Med 247:43-52. 2000....
- Low serum beta-carotene reflects immune activation in patients with coronary artery diseaseL Jonasson
Department of Cardiology, Heart Center, University Hospital, S 581 85 Linkoping, Sweden
Nutr Metab Cardiovasc Dis 13:120-5. 2003..An immunomodulatory effect of antioxidants has been proposed. The aim of the study was to investigate whether an increased immune response in CAD patients was associated with suppressed circulating levels of antioxidant vitamins...